RxSight Q4 revenue $16.1M (+91% YoY); FY22 revenue $49.0M (+117%); guides FY23 rev $78-83M

RxSight, Inc.

Q4 2022 revenue $16.1M, up 91% YoY; LAL procedure volumes up 208% to 9,123 units; LDD installed base 400 (+94% YoY).
Full year 2022 revenue $49.0M, up 117% YoY; sold 195 LDDs and 25,284 LALs.
FY23 revenue guidance $78-83M (59-69% growth); gross margin guidance 52-54% (up from 43.5% in FY22).
Net loss Q4 $(15.6)M ($0.56 loss per share); adjusted net loss $(12.6)M ($0.45 loss per share).
Completed public offering of 4.6M shares (including underwriter option) at $12.50/share in Feb 2023, raising ~$57.5M gross.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RxSight, Inc. reported the three and twelve-months ended December 31, 2022 results: revenue $16.1 million, net income $(15.6) million, EPS $(0.56) per basic and diluted share. Guidance initiated.

Period: the three and twelve-months ended December 31, 2022
Revenue: $16.1 million
Net income: $(15.6) million
EPS: $(0.56) per basic and diluted share
Guidance: initiated
Result: reported results

Exact text from the filing

today reported financial results for the three months and full year ended December 31, 2022. Key Quarterly and Full Year Highlights • Recognized fourth quarter 2022 revenue of $16.1 million, an increase of 91% compared to the fourth quarter of 2021, reflecting: • The sale of 57 Light Delivery Devices (LDDTMs), representing a 27% unit increase from the fourth quarter

View on SEC.gov

Browse all earnings releases →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006234

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.